Healthcare Services

A Significant Growth Driver for the Viral Vectors And Plasmid DNA Manufacturing Market Is the Increasing Gene Therapies Drive Growth In Viral Vectors And Plasmid DNA Manufacturing Market

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Viral Vectors And Plasmid DNA Manufacturing Market By 2030 Starting From Its 2026 Size?

The size of the viral vectors and plasmid dna manufacturing market has seen exponential growth in recent years. This market is projected to expand from $7.11 billion in 2025 to reach $8.79 billion by 2026, achieving a compound annual growth rate (CAGR) of 23.7%. Historically, this growth was driven by factors such as an increase in gene therapy research programs, the expansion of vaccine development initiatives, a rise in academic and clinical research funding, the early commercialization of cell therapies, and advancements in molecular biology techniques.

The market size for viral vectors and plasmid DNA manufacturing is anticipated to experience substantial growth in the upcoming years. It is projected to reach $20.36 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.4%. This expansion during the forecast period is primarily attributed to increasing approvals of gene and cell therapies, a rising demand for commercial-scale production, the broadening of CMO partnerships, a heightened focus on treatments for rare diseases, and ongoing innovation in vector design and production efficiency. Key trends anticipated in the forecast period encompass the increasing deployment of scalable viral vector manufacturing platforms, a rising adoption of single-use bioprocessing systems, a growing demand for high-purity plasmid dna, the expansion of contract manufacturing capacity, and an enhanced focus on regulatory-compliant production.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20690&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Viral Vectors And Plasmid DNA Manufacturing Market?

The expanding pipeline of gene therapies is anticipated to stimulate the growth of the viral vectors and plasmid DNA manufacturing market in the coming years. Gene therapy involves the introduction, removal, or alteration of genetic material within a person’s cells to treat or prevent disease. The advancement of gene therapy is vital, fueled by rising investments in biotechnology research and development, coupled with a deeper understanding of the genetic and cellular mechanisms underlying various diseases. Viral vectors and plasmid DNA manufacturing are instrumental in delivering therapeutic genes into patients’ cells, facilitating the molecular-level treatment of genetic disorders. For instance, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, the count of gene therapies in Phase III clinical trials increased by 10% in Q3 2023, representing the first quarterly rise since Q3 2022. This demonstrates that the growing number of gene therapies is a primary driver for the viral vectors and plasmid DNA manufacturing market.

Which Segment Categories Define The Viral Vectors And Plasmid DNA Manufacturing Market?

The viral vectors and plasmid dna manufacturing market covered in this report is segmented –

1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Viral Vector, Non-Viral Vector

2) By Scale Of Operation: Preclinical, Clinical, Commercial

3) By Therapeutic Area: Oncological Disorders, Rare Diseases, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musculoskeletal Disorders, Blood Disorders, Immunological Disorders, Other Disorders

4) By Application Area: Gene Therapies, Cell Therapies, Vaccines

5) By Type Of Manufacturer: In-house Manufacturers, Contract Manufacturing Organizations

Subsegments:

1) By Plasmid Deoxyribonucleic Acid (DNA): Linear Plasmid DNA, Circular Plasmid DNA, High-Copy Plasmid DNA, Low-Copy Plasmid DNA

2) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral Vectors (AAV), Retroviral Vectors

3) By Non-Viral Vector: Liposome-Based Vectors, Polymer-Based Vectors, Nanoparticle-Based Vectors, Electroporation-Based Vectors

Which Trends Are Shaping The Future Of The Viral Vectors And Plasmid DNA Manufacturing Market?

Leading companies within the viral vectors and plasmid DNA manufacturing market are increasingly pursuing strategic alliances to broaden their production capabilities, enhance technological expertise, and accelerate the global advancement and commercialization of gene therapies. These collaborations facilitate the sharing of resources and infrastructure among companies, consequently boosting overall production capacity to address the escalating demand for gene therapies. For example, in June 2024, Charles River Laboratories International Inc., a US-based preclinical and clinical contract research organization, along with Captain T Cell, a spinoff from the renowned Max Delbrück Center in Berlin, Germany, initiated a program agreement for plasmid DNA and retrovirus vector production. This partnership offers Captain T Cell access to well-established contract development and manufacturing (CDMO) services and advisory support. Moreover, it seeks to expedite the transition of a novel TCR-T cell therapy, designed to target solid tumors, from preclinical research into clinical trials.

Who Are The Top Companies Competing In The Viral Vectors And Plasmid DNA Manufacturing Market?

Major companies operating in the viral vectors and plasmid dna manufacturing market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Catalent Inc., Revvity Inc., Wuxi Biologics Inc., FUJIFILM Diosynth Biotechnologies, Miltenyi Biotec GmbH, Aldevron LLC, Takara Bio Inc., Poseida Therapeutics Inc., RegenxBio Inc., Cobra Biologics, Finvector Vision Therapies Limited, Batavia Biosciences B.V., uniQure N.V., Addgene Inc., BioNTech IMFS GmbH, Creative Biogene Inc., Genezen Laboratories Inc., Virovek Incorporation, Waisman Biomanufacturing, Axplora GmbH

Read the full viral vectors and plasmid dna manufacturing market report here:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-manufacturing-global-market-report

Which Regions Are Projected To Dominate The Viral Vectors And Plasmid DNA Manufacturing Market In The Coming Years?

North America was the largest region in the viral vectors and plasmid DNA manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vectors and plasmid dna manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Viral Vectors And Plasmid DNA Manufacturing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20690&type=smp

Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Manufacturing Market 2026, By The Business Research Company

Bacterial And Plasmid Vector Global Market Report

https://www.thebusinessresearchcompany.com/report/bacterial-and-plasmid-vector-global-market-report

Prenatal Dna Sequencing Global Market Report

https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report

Explosive Ordnance Disposal Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/explosive-ordnance-disposal-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795